Wells Fargo & Company – Consensus Indicates Potential 16.4% Upside

DirectorsTalk Interviews

Wells Fargo & Company found using ticker (WFC) now have 24 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The range between the high target price and low target price is between 65 and 44 calculating the mean target price we have 52.65. With the stocks previous close at 45.23 this would indicate that there is a potential upside of 16.4%. The day 50 moving average is 43.1 and the 200 day moving average is 47.36. The company has a market cap of $171,560m. Find out more information at: https://www.wellsfargo.com

The potential market cap would be $199,704m based on the market concensus.

Wells Fargo & Company, a diversified financial services company, provides banking, investment, mortgage, and consumer and commercial finance products and services in the United States and internationally. It operates through four segments: Consumer Banking and Lending; Commercial Banking; Corporate and Investment Banking; and Wealth and Investment Management. The Consumer Banking and Lending segment offers diversified financial products and services for consumers and small businesses. Its financial products and services include checking and savings accounts, and credit and debit cards, as well as home, auto, personal, and small business lending services. The Commercial Banking segment provides financial solutions to private, family owned, and certain public companies. Its products and services include banking and credit products across various industry sectors and municipalities, secured lending and lease products, and treasury management services. The Corporate and Investment Banking segment offers a suite of capital markets, banking, and financial products and services to corporate, commercial real estate, government, and institutional clients. Its products and services comprise corporate banking, investment banking, treasury management, commercial real estate lending and servicing, equity, and fixed income solutions, as well as sales, trading, and research capabilities services. The Wealth and Investment Management segment provides personalized wealth management, brokerage, financial planning, lending, private banking, and trust and fiduciary products and services to affluent, high-net worth, and ultra-high-net worth clients. It also operates through financial advisors. Wells Fargo & Company was founded in 1852 and is headquartered in San Francisco, California.

Share on:
Find more news, interviews, share price & company profile here for:

    Likewise granted approval for 20,000 sq ft expansion of Newport facility

    Likewise Group has received planning permission to extend its Newport warehouse by 20,000 sq ft, creating a 55,000 sq ft distribution hub. The development will be funded through internal cash flow.

    Cerillion secures £17.3m follow-on contracts with major European customer

    Cerillion has signed two agreements worth a combined £17.3 million with an existing European customer, following an £8 million services contract announced in May 2025.

    Avation reports US$110m revenue and strengthened balance sheet for FY25

    Avation expects revenue of around US$110 million for the year to 30 June 2025. The company has reduced outstanding bond debt to US$298 million through repurchases and improved its credit ratings with Moody’s and Fitch.

    JPMorgan European Discovery Trust reports strong performance uplift in latest factsheet

    JPMorgan European Discovery Trust reported a 5.37% share price rise in July 2025, outpacing NAV and its benchmark. Year-to-date, the share price is up 34.17%, supported by strong small-cap performance and effective stock selection.

    Golden Matrix reports record August revenue of $17.8m, up 18% year-on-year

    Golden Matrix posted record August revenues of $17.8m, up 18% from last year, with July revenues also rising 24% to $15.7m. Strong performance came from Meridianbet’s sports betting and RKings’ tournaments, positioning the group for record Q3 results.

    HUTCHMED to present new lung cancer and oncology data at WCLC and CSCO 2025

    HUTCHMED announced that updated data on savolitinib in NSCLC and other pipeline compounds will be presented at the World Conference on Lung Cancer in Barcelona and the CSCO Annual Meeting in China this September. Presentations include studies on savolitinib, surufatinib, fruquintinib and first-in-human results for HMPL-653.

      Search

      Search